Ohr Pharmaceuticals (NASDAQ:OHRP) will release its earnings data after the market closes on Wednesday, December 20th.
Shares of Ohr Pharmaceuticals (NASDAQ OHRP) opened at $1.42 on Wednesday. Ohr Pharmaceuticals has a 52-week low of $0.56 and a 52-week high of $1.90.
An institutional investor recently raised its position in Ohr Pharmaceuticals stock. Vanguard Group Inc. raised its holdings in Ohr Pharmaceuticals, Inc. (NASDAQ:OHRP) by 0.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 812,418 shares of the biotechnology company’s stock after purchasing an additional 5,481 shares during the quarter. Vanguard Group Inc. owned 1.45% of Ohr Pharmaceuticals worth $520,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 8.40% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/13/ohr-pharmaceuticals-ohrp-scheduled-to-post-earnings-on-wednesday.html.
Ohr Pharmaceuticals Company Profile
OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.
Receive News & Ratings for Ohr Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.